Cargando…

4. MenACWY-TT Long-Term Antibody Persistence Following Adolescent Vaccination and Evaluation of a Booster Dose: A Review of Clinical Data

BACKGROUND: A peak in meningococcal carriage and invasive meningococcal disease (IMD) occurs during adolescence and young adulthood. In the United States, preventive vaccination with a quadrivalent meningococcal (MenACWY) conjugate vaccine is recommended at age 11–12 years, with a booster dose given...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peyrani, Paula, Webber, Chris, Burman, Cindy, Balmer, Paul, Perez, John L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776109/ http://dx.doi.org/10.1093/ofid/ofaa439.049

Ejemplares similares

1478. Efficacy and Safety of a Booster Dose of the MenACWY-TT Vaccine Administered 10 Years After Primary Vaccination with MenACWY-TT or MenACWY-PS
por: Quiambao, Beatriz, et al.
Publicado: (2019)

2722 B. Efficacy and Safety of a Booster Dose of the MenACWY-TT Vaccine Administered 10 Years After Primary Vaccination with MenACWY-TT or MenACWY-PS
por: Quiambao, Beatriz, et al.
Publicado: (2019)

3. A Review of the Clinical Development of MenACWY-TT, a Quadrivalent Meningococcal Vaccine Conjugated to Tetanus Toxoid, in Adolescents
por: Peyrani, Paula, et al.
Publicado: (2020)

14. Postmarketing Safety Experience With MenACWY-TT
por: Serra, Lidia, et al.
Publicado: (2021)

Real-world impact and effectiveness of MenACWY-TT
por: Villena, Rodolfo, et al.
Publicado: (2023)

Ten-Year Antibody Persistence and Booster Response to MenACWY-TT Vaccine After Primary Vaccination at 1-10 Years of Age
por: Vesikari, Timo, et al.
Publicado: (2020)

A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years
por: Borja-Tabora, Charissa Fay Corazon, et al.
Publicado: (2020)

Tolerability of MenACWY-TT vaccination in adolescents in the Netherlands; a cross-sectional study
por: Kemmeren, J. M., et al.
Publicado: (2021)

Bactericidal antibodies against hypervirulent Neisseria meningitidis C field strains following MenC-CRM or MenACWY-CRM priming and MenACWY-CRM booster in children
por: Giuliani, Marzia Monica, et al.
Publicado: (2020)

Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents
por: Quiambao, Beatriz P., et al.
Publicado: (2016)

Assessing the Role of Infant and Toddler MenACWY Immunisation in the UK: Does the Adolescent MenACWY Programme Provide Sufficient Protection?
por: Schley, Katharina, et al.
Publicado: (2023)

Immunogenicity of MenACWY-CRM in Korean Military Recruits: Influence of Tetanus-Diphtheria Toxoid Vaccination on the Vaccine Response to MenACWY-CRM
por: Kim, Han Wool, et al.
Publicado: (2016)

1085 Persistence of Meningococcal Bactericidal Antibodies and Booster Response at 60-Months of Age in Children Who Received Infant Or Toddler Doses of MenACWY-CRM Conjugate Vaccine
por: Klein, Nicola P., et al.
Publicado: (2014)

Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children
por: Knuf, Markus, et al.
Publicado: (2012)

One-year antibody persistence and safety of a 4-dose schedule of MenACWY-CRM in healthy infants from South Korea
por: Lee, Hoan-Jong, et al.
Publicado: (2019)

Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile
por: Graña, María Gabriela, et al.
Publicado: (2021)

Epidemiologic Trends, Global Shifts in Meningococcal Vaccination Guidelines, and Data Supporting the Use of MenACWY-TT Vaccine: A Review
por: Presa, Jessica, et al.
Publicado: (2019)

Review of clinical studies comparing meningococcal serogroup C immune responses induced by MenACWY-TT and monovalent serogroup C vaccines
por: Serra, Lidia, et al.
Publicado: (2021)

1080 Antibody Persistence 5 Years After Vaccination at 2 to 10 Years of Age With Quadrivalent MenACWY-CRM Conjugate Vaccine, And Responses To a Booster Vaccination
por: Block, Stanley L., et al.
Publicado: (2014)

2459. Meningococcal ACWY (MenACWY) Vaccination of Adolescents in the United States: How Compliant Are We With the Advisory Committee on Immunization Practices (ACIP) Recommendations?
por: Cheng, Wendy, et al.
Publicado: (2018)

Fully Liquid MenACWY-CRM Vaccine: Results from an Integrated Safety Analysis
por: Vir Singh, Puneet, et al.
Publicado: (2022)

2456. Immunogenicity and Safety of a MenACWY-CRM Booster Dose 4–6 Years After Primary Quadrivalent Meningococcal Conjugate Vaccination in Healthy US Adolescents and Adults
por: Tipton, Mary, et al.
Publicado: (2018)

Adolescent and parental decision-making for the MenACWY vaccination: influential predictors and parental-adolescent differences among households in the Netherlands
por: Oostdijk, C., et al.
Publicado: (2023)

Modelling the impact of COVID-19 and routine MenACWY vaccination on meningococcal carriage and disease in the UK
por: Hadley, Liza, et al.
Publicado: (2023)

Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age
por: Marshall, Gary S., et al.
Publicado: (2022)

Modelling the impact of COVID-19 and routine MenACWY vaccination on meningococcal carriage and disease in the UK – ERRATUM
por: Hadley, Liza, et al.
Publicado: (2023)

Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018
por: Knol, Mirjam J, et al.
Publicado: (2018)

6. Pentavalent Meningococcal (MenABCWY) Vaccine is Safe and Well Tolerated With Immunogenicity Noninferior to Coadministered MenB-FHbp and MenACWY-CRM in a Phase 2 Study of Healthy Adolescents and Young Adults
por: Peterson, James, et al.
Publicado: (2020)

What school-level and area-level factors influenced HPV and MenACWY vaccine coverage in England in 2016/2017? An ecological study
por: Tiley, Karen, et al.
Publicado: (2019)

Psychosocial and organizational barriers and facilitators of meningococcal vaccination (MenACWY) acceptance among adolescents and parents during the Covid-19 pandemic: a cross-sectional survey
por: Widdershoven, Veja, et al.
Publicado: (2022)

Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2–10-year-old children: results of an open, randomised, controlled study
por: Knuf, Markus, et al.
Publicado: (2013)

Immunogenicity and Safety of Investigational MenABCWY Vaccine and of 4CMenB and MenACWY Vaccines Administered Concomitantly or Alone: a Phase 2 Randomized Study of Adolescents and Young Adults
por: Beran, Jiří, et al.
Publicado: (2021)

A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine
por: Ruiz Garcia, Yara, et al.
Publicado: (2021)

Does social deprivation correlate with meningococcal MenACWY, Hib/MenC and 4CMenB/Meningococcal Group B vaccine uptake in Northern Ireland?
por: Brennan, Orlaith C., et al.
Publicado: (2022)

Correction to: A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine
por: Ruiz Garcia, Yara, et al.
Publicado: (2021)

Cross-Sectional Study of University Students’ Attitudes to ‘On Campus’ Delivery of COVID-19, MenACWY and MMR Vaccines and Future-Proofing Vaccine Roll-Out Strategies
por: Webb, Adam, et al.
Publicado: (2022)

Immunogenicity and Safety of a Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine (MenACWY-TT) Administered to Adults Aged 56 Years and Older: Results of an Open-Label, Randomized, Controlled Trial
por: Dbaibo, Ghassan, et al.
Publicado: (2013)

Use of MenACWY-CRM Vaccine in Children Aged 2 Through 23 Months at Increased Risk for Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2013
por: MacNeil, Jessica R., et al.
Publicado: (2014)

Post-Marketing Surveillance Observational Study of Quadrivalent Meningococcal Diphtheria Toxoid Conjugate Vaccine (MenACWY-DT, MCV4/Menactra(®)) in the Republic of Korea, 2014–2019
por: Kim, Hee Soo, et al.
Publicado: (2021)

Immunological non-inferiority of a new fully liquid presentation of the MenACWY-CRM vaccine to the licensed vaccine: results from a randomized, controlled, observer-blind study in adolescents and young adults
por: Díez-Domingo, Javier, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r3j5jjo5c8l9urj0als9cq2j24